Skip to main content

Table 1 The expression of the top 20 upregulated and downregulated genes in the cetuximab resistant CACO2

From: Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer

Gene symbol Normalized Signal Value Log [fold change] P value Adjustive p value
Sensitive Resistant
Sam.1 Sam.2 Sam.3 Sam.1 Sam.2 Sam.3
Top 20 of up-regulated genes
 DRD2 1.253 1.265 1.252 7.414 7.471 7.331 6.149 2.76E–09 5.19E–05
 SLC2A5 8.931 9.006 9.037 13.002 12.996 12.980 4.001 2.62E–08 9.87E–05
 CADM1 4.659 4.421 4.556 9.133 9.344 9.152 4.664 4.91E–08 1.11E–04
 RTP3 1.232 1.300 1.161 4.731 4.881 4.823 3.581 8.34E–08 1.14E–04
 NPR2 6.365 6.349 6.191 10.112 10.297 10.310 3.938 9.25E–08 1.16E–04
 SERPINF1 10.281 10.168 10.135 13.543 13.716 13.685 3.453 1.29E–07 1.26E–04
 BASP1 6.890 6.446 6.407 11.922 12.156 12.069 5.468 1.33E–07 1.26E–04
 LAMA1 6.237 6.392 6.334 9.733 9.873 9.949 3.531 1.42E–07 1.26E–04
 THPO 1.271 1.275 1.418 4.485 4.429 4.562 3.171 1.75E–07 1.26E–04
 ACTA1 4.330 3.837 4.273 9.829 9.596 9.503 5.496 1.80E–07 1.26E–04
 SERPINF2 11.096 11.257 10.992 14.287 14.346 14.294 3.194 2.59E–07 1.35E–04
 ANXA8 9.699 9.805 9.662 12.950 13.168 12.871 3.274 3.77E–07 1.73E–04
 DPYSL3 7.688 7.165 7.810 12.588 12.744 12.676 5.115 4.15E–07 1.82E–04
 PDGFRA 1.312 1.304 1.231 5.091 5.216 4.782 3.748 4.25E–07 1.82E–04
 SDC2 4.645 4.510 4.744 7.533 7.547 7.725 2.968 5.37E–07 2.10E–04
 ORM1 12.007 12.089 11.909 14.634 14.613 14.758 2.667 5.43E–07 2.10E–04
 ORM2 12.062 12.209 12.006 14.728 14.646 14.739 2.612 5.85E–07 2.10E–04
 ADM 10.696 10.620 10.518 13.201 13.321 13.175 2.621 5.92E–07 2.10E–04
 ADAM19 9.666 9.526 9.323 12.874 12.710 12.676 3.248 6.38E–07 2.22E–04
 CCDC3 9.139 9.112 8.781 12.448 12.206 12.351 3.324 9.05E–07 2.59E–04
Top 20 of down-regulated genes
 GC 6.719 6.693 6.902 1.271 1.278 1.263 –5.500 8.90E–09 6.23E–05
 SCIN 6.839 6.926 7.093 1.350 1.309 1.335 –5.621 9.94E–09 6.23E–05
 ST6GALNAC1 7.759 7.546 7.389 1.269 1.309 1.356 –6.253 1.39E–08 6.51E–05
 PADI2 8.533 8.655 8.104 1.339 1.256 1.373 –7.108 3.18E–08 9.95E–05
 MUC13 14.179 13.905 14.478 7.486 7.521 7.534 –6.674 4.05E–08 1.09E–04
 SULF2 9.285 8.985 9.273 3.737 3.522 3.850 –5.478 5.92E–08 1.11E–04
 COL17A1 8.492 8.749 8.525 2.545 2.030 2.235 –6.319 6.07E–08 1.11E–04
 FAM83E 10.754 10.695 10.635 6.944 7.056 6.897 –3.729 6.48E–08 1.11E–04
 HLA-DMB 5.666 5.548 5.337 1.177 1.237 1.244 –4.298 8.23E–08 1.14E–04
 NPAS2 5.506 5.310 5.640 1.250 1.186 1.173 –4.282 8.47E–08 1.14E–04
 PNLIPRP2 9.009 8.923 8.898 4.505 4.836 4.560 –4.310 1.04E–07 1.22E–04
 LCN2 11.287 11.659 11.027 4.564 4.442 4.834 –6.711 1.24E–07 1.26E–04
 SRPX 9.803 9.612 9.507 5.937 5.942 5.842 –3.734 1.53E–07 1.26E–04
 HOXB9 10.762 10.582 10.682 7.503 7.485 7.573 –3.155 1.66E–07 1.26E–04
 BTNL3 5.120 5.170 5.485 1.188 1.231 1.215 –4.047 1.77E–07 1.26E–04
 TMC5 7.201 6.746 7.401 1.274 1.203 1.339 –5.844 1.77E–07 1.26E–04
 APOBEC1 6.060 5.632 6.092 1.210 1.170 1.156 –4.749 1.78E–07 1.26E–04
 S100A9 10.469 10.404 9.896 3.540 3.948 3.972 –6.436 2.00E–07 1.31E–04
 DDIT4L 6.599 6.789 7.249 1.229 1.281 1.306 –5.607 2.07E–07 1.31E–04
 PI3 13.824 13.941 13.611 9.571 9.226 9.378 –4.400 2.12E–07 1.31E–04